Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, siltuximab (Sylvant®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus‑8 (HHV‑8) negative. |
||
|
||
Medicine details |
||
| Medicine name | siltuximab (Sylvant®) | |
| Formulation | 100 mg powder for concentrate for solution for infusion, 400 mg powder for concentrate for solution for infusion | |
| Reference number | 1329 | |
| Indication | For the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus‑8 (HHV‑8) negative. |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 24/09/2014 | |
| Date of issue | 25/09/2014 | |